
    
      Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally
      Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene
      Mutation: A Multicenter, Open-Label, Randomized, Controlled Phase III Study (ACROSS2)
    
  